我們已在上線! 進一步了解
KRBP

Kiromic BioPharma, Inc. Common Stock

已下市

KRBP已於2023年9月13日下市。

 

關於: Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

員工: 31

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於KRBP的最新新聞文章。

價格圖表採用Lightweight Charts™實作